CagriSema REDEFINE: why amylin + semaglutide beats semaglutide alone
CagriSema is Novo Nordisk's combination of semaglutide and cagrilintide — a long-acting amylin analog. Phase 3 REDEFINE trial results showed mean weight loss of ~20.4% in CagriSema arms versus ~16.1% in semaglutide monotherapy. Amylin is the often-overlooked third axis of appetite control.
What amylin does
Amylin is a 37-residue peptide hormone secreted alongside insulin by pancreatic beta cells. Its physiological roles:
- Slows gastric emptying (synergistic with GLP-1).
- Suppresses glucagon secretion after meals.
- Acts on brainstem satiety pathways (area postrema) — distinct from GLP-1's hypothalamic effects.
- Reduces food reward processing in higher brain centers.
The brainstem and hypothalamic appetite pathways are partly independent. Hitting both produces additive (sometimes synergistic) satiety beyond either alone.
Why cagrilintide is a separate molecule
Natural amylin has a very short half-life (~13 minutes) and tends to aggregate into amyloid fibrils — a structural problem that makes it unsuitable for a long-acting drug. Cagrilintide is engineered:
- Multiple amino acid substitutions to prevent fibril formation.
- Acylation with a fatty-acid chain for albumin binding and long half-life (~7 days, matching semaglutide).
- Once-weekly subq injection — same cadence as semaglutide.
The matched half-life is what makes the combination practical: both arms maintain steady-state plasma over a weekly dose.
REDEFINE trial design and results
| Property | REDEFINE-1 |
|---|---|
| Population | ~3,400 adults with overweight or obesity, no T2D |
| Duration | 68 weeks |
| Arms | CagriSema (2.4 mg semaglutide + 2.4 mg cagrilintide), semaglutide alone, cagrilintide alone, placebo |
| Arm | Weight loss at 68 weeks |
|---|---|
| Placebo | ~3.0% |
| Cagrilintide monotherapy (2.4 mg) | ~11.5% |
| Semaglutide monotherapy (2.4 mg) | ~16.1% |
| CagriSema (2.4 mg + 2.4 mg) | ~20.4% |
The combination produced ~4.3 percentage points more weight loss than semaglutide alone, and approached tirzepatide-class numbers (~21% in SURMOUNT-1) — though through a different mechanistic combination.
How CagriSema compares to tirzepatide
| Drug | Mechanism | Mean weight loss | Dosing |
|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 mono-agonist | ~14.9–16.1% | Weekly subq |
| Tirzepatide 15 mg | GLP-1 + GIP dual agonist | ~20.9% | Weekly subq |
| CagriSema 2.4 + 2.4 mg | GLP-1 + amylin combination | ~20.4% | Weekly subq |
| Retatrutide 12 mg | GLP-1 + GIP + glucagon triple | ~24.2% (Phase 2) | Weekly subq |
CagriSema and tirzepatide are close in efficacy. Different mechanisms reach similar destinations.
Side-effect picture
CagriSema's side-effect profile is similar to semaglutide alone — nausea, vomiting, diarrhea, constipation — with marginally higher rates of GI events in early titration weeks. The amylin component appears not to add a significant new side-effect class. Discontinuation rates were comparable.
When CagriSema will be available
FDA approval is expected in 2026–2027 pending REDEFINE's full data package and regulatory review. Novo Nordisk's manufacturing capacity is the limiting factor for both semaglutide and any cagrilintide-containing product. Expect availability constraints in the first 12–18 months after approval.
What this means for users
- If currently on semaglutide and plateaued, CagriSema is a logical upgrade path within Novo's family of products. Different mechanism than switching to tirzepatide.
- If targeting maximum weight loss, choice between CagriSema and tirzepatide will come down to tolerability and availability — efficacy is similar.
- Pricing is uncertain. CagriSema combines two molecules into one product; pricing strategy hasn't been disclosed but is unlikely to be lower than semaglutide monotherapy.
FAQ
Is cagrilintide available separately?
Not yet for general clinical use. Novo Nordisk's primary commercial path is CagriSema (the combination). Cagrilintide monotherapy may or may not be commercialized depending on Phase 3 follow-up.
How does CagriSema compare to taking semaglutide and a separate amylin analog?
The matched pharmacokinetics matter. Combining semaglutide with pramlintide (a short-acting amylin analog used for diabetes) doesn't work the same way because pramlintide is dosed at meals, not weekly.
Does CagriSema increase pancreatic stress?
No suggestion in trial data. Amylin is naturally co-secreted with insulin; supplementing the amylin signal doesn't increase beta-cell demand. The opposite is more likely — endogenous amylin secretion may decrease in response to exogenous cagrilintide.
Is CagriSema better for diabetes?
Not specifically. Semaglutide alone is the diabetes workhorse; CagriSema's edge is weight loss in obesity without diabetes. Trials in T2D are ongoing.
Related reading
Compare therapies side by side
Peptide Protocol's library puts every approved and investigational therapy in one place, with mechanism, dosing, and weight-loss numbers.
Get the iPhone app →Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.